Get Involved
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Study Purpose
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 12 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Has surgically resected and histologically or pathologically confirmed diagnosis of Stage IIB and IIC (pathological or clinical), III, or IV cutaneous melanoma per the American Joint Committee on Cancer (AJCC) eighth edition guidelines.
- - Has not received any prior systemic therapy for melanoma beyond surgical resection.
- - Has had no more than 12 weeks between final surgical resection and randomization.
- - Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART) - Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization.
- - Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.
Exclusion Criteria:
- - Has ocular, mucosal, or conjunctival melanoma.
- - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.
- - Has not adequately recovered from major surgical procedure or has ongoing surgical complications.
- - Has received prior radiotherapy within 2 weeks of start of study intervention or has had a history of radiation pneumonitis.
- - Received a live or live attenuated vaccine within 30 days before the first dose of study intervention.
- - Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.
- - Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- - Has an active autoimmune disease that has required systemic treatment in past 2 years.
- - Has an active infection requiring systemic therapy.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT05665595 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Merck Sharp & Dohme LLC |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Medical Director |
| Principal Investigator Affiliation | Merck Sharp & Dohme LLC |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, New Zealand, Poland, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Melanoma |
| Study Website: | View Trial Website |
With Amendment 4, participants will discontinue treatment with pembrolizumab/vibostolimab. The protocol-specified futility analysis of the primary outcome measure was completed with a data cut-off of 06-Mar-2024 (Primary Completion Date) and served as the final analysis of the primary outcome measure. Per protocol, 192 participants enrolled after the primary completion date and will be analyzed in the End of Trial analysis.
Arms
Experimental: Pembrolizumab/Vibostolimab
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
Active Comparator: Pembrolizumab
Participants receive 200 mg pembrolizumab via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
Interventions
Biological: - Pembrolizumab/Vibostolimab
Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
Biological: - Pembrolizumab
Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Moores Cancer Center ( Site 0116)
La Jolla 5363943, California 5332921, 92093-0698
Status
Address
The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123)
Los Angeles 5368361, California 5332921, 90025
Status
Address
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131)
Los Angeles 5368361, California 5332921, 90095
Status
Address
California Pacific Medical Center - Pacific Campus ( Site 0111)
San Francisco 5391959, California 5332921, 94115
Status
Address
UCSF Medical Center at Mission Bay ( Site 0130)
San Francisco 5391959, California 5332921, 94158
Status
Address
The Melanoma & Skin Cancer Institute ( Site 0120)
Englewood 5421250, Colorado 5417618, 80113
Status
Address
Georgetown University Medical Center ( Site 0144)
Washington D.C. 4140963, District of Columbia 4138106, 20007
Status
Address
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110)
Miami 4164138, Florida 4155751, 33136
Status
Address
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 0124)
Tampa 4174757, Florida 4155751, 33612
Status
Address
Northwestern Memorial Hospital ( Site 0109)
Chicago 4887398, Illinois 4896861, 60611
Status
Address
Advocate Medical Group-Oncology ( Site 0102)
Park Ridge 4905367, Illinois 4896861, 60068
Status
Address
University of Iowa-Holden Comprehensive Cancer Center ( Site 0107)
Iowa City 4862034, Iowa 4862182, 52242
Status
Address
Henry Ford Hospital ( Site 0133)
Detroit 4990729, Michigan 5001836, 48202
Status
Address
Comprehensive Cancer Centers of Nevada ( Site 0142)
Las Vegas 5506956, Nevada 5509151, 89169
Status
Address
R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0132)
Lake Success 5123853, New York 5128638, 11042
Status
Address
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0146)
Mineola 5127134, New York 5128638, 11501
Status
Address
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113)
New York 5128581, New York 5128638, 10016
Status
Address
Icahn School of Medicine at Mount Sinai ( Site 0118)
New York 5128581, New York 5128638, 10029
Status
Address
Weill Cornell Medical College ( Site 0115)
New York 5128581, New York 5128638, 10065
Status
Address
Levine Cancer Institute ( Site 0138)
Charlotte 4460243, North Carolina 4482348, 28204
Status
Address
Sanford Fargo Medical Center ( Site 0127)
Fargo 5059163, North Dakota 5690763, 58102
Status
Address
Children's Hospital of Pittsburgh ( Site 0141)
Pittsburgh 5206379, Pennsylvania 6254927, 15224
Status
Address
UPMC Hillman Cancer Center ( Site 0135)
Pittsburgh 5206379, Pennsylvania 6254927, 15232
Status
Address
Sanford Cancer Center ( Site 0125)
Sioux Falls 5231851, South Dakota 5769223, 57104
Status
Address
The West Clinic, PLLC dba West Cancer Center ( Site 0119)
Germantown 4624601, Tennessee 4662168, 38138
Status
Address
St. Jude Children's Research Hospital ( Site 0106)
Memphis 4641239, Tennessee 4662168, 38105
Status
Address
Vanderbilt University Medical Center ( Site 0139)
Nashville 4644585, Tennessee 4662168, 37232
Status
Address
University of Texas MD Anderson Cancer Center ( Site 0145)
Houston 4699066, Texas 4736286, 77030
Status
Address
Inova Schar Cancer Institute ( Site 0103)
Fairfax 4758023, Virginia 6254928, 22031
Status
Address
University of Wisconsin Hospital and Clinics ( Site 0108)
Madison 5261457, Wisconsin 5279468, 53792
International Sites
Status
Address
Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204)
Ciudad Autónoma de Buenos Aires, Buenos Aires 3435907, C1027AAP
Status
Address
Instituto Alexander Fleming-Alexander Fleming ( Site 0209)
Ciudad Autónoma de Buenos Aires, Buenos Aires 3435907, C1426ANZ
Status
Address
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200)
Buenos Aires 3435910, Buenos Aires F.D. 3433955, C1431FWO
Status
Address
Instituto de Oncología de Rosario ( Site 0206)
Rosario 3838583, Santa Fe Province 3836276, S2000KZE
Status
Address
Sanatorio Finochietto ( Site 0212)
Buenos Aires 3435910, , C1187AAN
Status
Address
Clinica Adventista Belgrano-Oncology ( Site 0211)
CABA, , C1430EGF
Status
Address
Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 1464)
Blacktown 2175411, New South Wales 2155400, 2148
Status
Address
Calvary Mater Newcastle-Medical Oncology ( Site 1462)
Waratah 10103871, New South Wales 2155400, 2298
Status
Address
Melanoma Institute Australia-Clinical Trials Unit ( Site 1450)
Wollstonecraft 9972972, New South Wales 2155400, 2065
Status
Address
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Brisbane 2174003, Queensland 2152274, 4029
Status
Address
Cairns Hospital-Clinical Research Unit ( Site 1458)
Cairns 2172797, Queensland 2152274, 4870
Status
Address
Gallipoli Medical Research Ltd-GMRF CTU ( Site 1451)
Greenslopes 9957342, Queensland 2152274, 4120
Status
Address
Tasman Oncology Research ( Site 1456)
Southport 2148928, Queensland 2152274, 4215
Status
Address
Royal Adelaide Hospital-RAH Cancer Centre ( Site 1457)
Adelaide 2078025, South Australia 2061327, 5000
Status
Address
Icon Cancer Centre Hobart ( Site 1465)
Hobart 2163355, Tasmania 2147291, 7000
Status
Address
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1455)
Melbourne 2158177, Victoria 2145234, 3000
Status
Address
One Clinical Research ( Site 1460)
Nedlands 2064874, Western Australia 2058645, 6009
Status
Address
Universitätsklinikum St. Pölten-Department of Dermatology ( Site 0606)
Sankt Pölten 2766429, Lower Austria 2770542, 3100
Status
Address
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0601)
Graz 2778067, Styria 2764581, 8036
Status
Address
Medizinische Universitaet Innsbruck-Univ Klinik für Dermatologie, Venerologie und Allergologie ( Sit
Innsbruck 2775220, Tyrol 2763586, 6020
Status
Address
Ordensklinikum Linz GmbH Elisabethinen-Dermatologie ( Site 0602)
Linz 2772400, Upper Austria 2769848, 4020
Status
Address
Medizinische Universität Wien-Department of Dermatology ( Site 0600)
Vienna 2761369, Vienna 2761367, 1090
Status
Address
Uniklinikum Salzburg-Department of Dermatology and Allergology ( Site 0604)
Salzburg 2766824, , 5020
Status
Address
GZA Ziekenhuizen campus Sint-Augustinus ( Site 0655)
Wilrijk 2783615, Antwerpen, 2610
Status
Address
Cliniques universitaires Saint-Luc ( Site 0652)
Brussels 2800866, Bruxelles-Capitale, Region de, 1200
Status
Address
Jessa Ziekenhuis ( Site 0656)
Hasselt 2796491, Limburg, 3500
Status
Address
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0653)
Yvoir 2783385, Namur, 5530
Status
Address
VITAZ-Medical Oncology ( Site 0654)
Sint-Niklaas 2786578, Oost-Vlaanderen, B-9100
Status
Address
UZ Leuven-General Medical Oncology ( Site 0650)
Leuven 2792482, Vlaams-Brabant, 3000
Status
Address
Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 0256)
Belo Horizonte 3470127, Minas Gerais 3457153, 30130090
Status
Address
Hospital de Cancer de Londrina-Clinical Research Unit ( Site 0252)
Londrina 3458449, Paraná 3455077, 86015-520
Status
Address
Associação Hospitalar Beneficente São Vicente de Paulo-Instituto do Câncer ( Site 0259)
Passo Fundo 3454857, Rio Grande do Sul 3451133, 99010-080
Status
Address
ANIMI - Unidade de Tratamento Oncologico ( Site 0255)
Lages 3458930, Santa Catarina 3450387, 88501001
Status
Address
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia ( Site 0262)
Santo André 3449701, São Paulo 3448433, 09060-870
Status
Address
A. C. Camargo Cancer Center ( Site 0258)
São Paulo 3448439, , 01509-010
Status
Address
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0004)
Ottawa 6094817, Ontario 6093943, K1H 8L6
Status
Address
Sunnybrook Research Institute ( Site 0003)
Toronto 6167865, Ontario 6093943, M4N 3M5
Status
Address
Princess Margaret Cancer Centre ( Site 0006)
Toronto 6167865, Ontario 6093943, M5G 2M9
Status
Address
Oncocentro Valdivia ( Site 0307)
Valdivia 3868707, Los Ríos Region 6693563, 5112129
Status
Address
FALP-UIDO ( Site 0303)
Santiago 3871336, Region M. de Santiago, 7500921
Status
Address
Oncovida ( Site 0304)
Santiago 3871336, Region M. de Santiago, 7510032
Status
Address
Clínica UC San Carlos de Apoquindo ( Site 0305)
Santiago 3871336, Region M. de Santiago, 7620002
Status
Address
Bradfordhill-Clinical Area ( Site 0302)
Santiago 3871336, Region M. de Santiago, 8420383
Status
Address
ONCOCENTRO APYS-ACEREY ( Site 0300)
Viña del Mar 3868121, Región de Valparaíso 3868621, 2520598
Status
Address
Bradford Hill Norte ( Site 0308)
Antofagasta 3899539, , 1240000
Status
Address
Beijing Ji Shui Tan Hospital ( Site 1657)
Beijing 1816670, Beijing Municipality 2038349, 100035
Status
Address
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 1650)
Beijing 1816670, Beijing Municipality 2038349, 100142
Status
Address
Chongqing University Cancer Hospital ( Site 1651)
Chongqing 1814906, Chongqing Municipality 1814905, 400030
Status
Address
Fujian Provincial Cancer Hospital ( Site 1659)
Fuzhou 1810821, Fujian 1811017, 350014
Status
Address
Sun Yat-sen University Cancer Center-melanoma ( Site 1655)
Guangzhou 1809858, Guangdong 1809935, 510060
Status
Address
Guangxi Medical University Affiliated Tumor Hospital ( Site 1668)
Nanning 1799869, Guangxi 1809867, 530021
Status
Address
Fourth Hospital of Hebei Medical University ( Site 1669)
Shijiazhuang 1795270, Hebei 1808773, 050035
Status
Address
The Third Hospital of Zhengzhou-Oncology ( Site 1653)
Zhengzhou 1784658, Henan 1808520, 450001
Status
Address
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 1664)
Wuhan 1791247, Hubei 1806949, 430022
Status
Address
The Second Xiangya Hospital of Central South University-Oncology ( Site 1673)
Changsha 1815577, Hunan 1806691, 410011
Status
Address
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (
Nanjing 1799962, Jiangsu 1806260, 210000
Status
Address
Jiangsu Province Hospital-Oncology Department ( Site 1663)
Nanjing 1799962, Jiangsu 1806260, 210029
Status
Address
The First Affiliated Hospital of Nanchang University ( Site 1652)
Nanchang 1800163, Jiangxi 1806222, 330006
Status
Address
The First Hospital of Jilin University-Oncology ( Site 1665)
Changchun 2038180, Jilin 2036500, 130021
Status
Address
Fudan University Shanghai Cancer Center ( Site 1658)
Shanghai 1796236, Shanghai Municipality 1796231, 200032
Status
Address
Shanxi Bethune Hospital ( Site 1660)
Taiyuan 1793511, Shanxi 1795912, 030032
Status
Address
West China Hospital, Sichuan University-Head and Neck Oncology ( Site 1667)
Chengdu 1815286, Sichuan 1794299, 610041
Status
Address
Tianjin Medical University Cancer Institute & Hospital-Biotherapy ( Site 1671)
Tianjin 1792947, Tianjin Municipality 1792943,
Status
Address
Xinjiang Medical University Cancer Hospital - Urumqi-Bone and Soft Tissue Department ( Site 1674)
Ürümqi 1529102, Xinjiang 1529047, 830000
Status
Address
Yunnan Province Cancer Hospital-Biotherapy Center ( Site 1666)
Kunming 1804651, Yunnan 1785694, 650106
Status
Address
Zhejiang Cancer Hospital-Oncology ( Site 1661)
Hangzhou 1808926, Zhejiang 1784764, 310022
Status
Address
Instituto de Cancerología ( Site 0356)
Medellín 3674962, Antioquia 3689815, 050025
Status
Address
Fundación Colombiana de Cancerología Clínica Vida ( Site 0355)
Medellín 3674962, Antioquia 3689815, 050030
Status
Address
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0358)
Bogotá 3688689, Bogota D.C. 3688685, 111321
Status
Address
Mediservis del Tolima IPS S.A.S ( Site 0357)
Ibagué 3680656, Tolima Department 3666951, 730006
Status
Address
Fundación Valle del Lili ( Site 0352)
Santiago de Cali 3687925, Valle del Cauca Department 3666313, 760032
Status
Address
Centre Hospitalier de Valence-Service de Dermatologie ( Site 0702)
Valence 2971053, Drome, 26953
Status
Address
Hopital Claude Huriez - CHU de Lille-Clinique de Dermatologie ( Site 0700)
Lille 2998324, Hauts-de-France 11071624, 59037
Status
Address
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu-Onco-Dermatology ( Site 0707)
Nantes 2990969, Loire-Atlantique, 44093
Status
Address
Institut de Cancérologie de l'Ouest-Oncologie Médicale ( Site 0706)
Saint-Herblain 2979590, Loire-Atlantique, 44805
Status
Address
Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi
Marseille 2995469, Provence-Alpes-Côte d'Azur Region 2985244, 13005
Status
Address
Centre Hospitalier de Pau ( Site 0708)
Pau 2988358, Pyrenees-Atlantiques, 64000
Status
Address
centre hospitalier lyon sud-Service de dermatologie ( Site 0714)
Pierre-Bénite 2987314, Rhone, 69310
Status
Address
Gustave Roussy-Dermatologie ( Site 0713)
Villejuif 2968705, Val-de-Marne, 94800
Status
Address
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0711)
Paris 2988507, , 75014
Status
Address
Universitaetsklinikum Heidelberg ( Site 0765)
Heidelberg 2907911, Baden-Wurttemberg 2953481, 69120
Status
Address
Universitätsmedizin Mannheim ( Site 0751)
Mannheim 2873891, Baden-Wurttemberg 2953481, 68167
Status
Address
Universitaetsklinikum Erlangen-Hautklinik ( Site 0750)
Erlangen 2929567, Bavaria 2951839, 91054
Status
Address
Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 0757)
München 2867713, Bavaria 2951839, 80337
Status
Address
Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude-Dermatologisches Zentrum ( Site 0754)
Buxtehude 2940451, Lower Saxony 2862926, 21614
Status
Address
Medizinische Hochschule Hannover ( Site 0758)
Hanover 2910831, Lower Saxony 2862926, 30625
Status
Address
Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0761)
Essen 2928810, North Rhine-Westphalia 2861876, 45147
Status
Address
Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 0759)
Minden 2871039, North Rhine-Westphalia 2861876, 32429
Status
Address
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0766)
Dresden 2935022, Saxony 2842566, 01307
Status
Address
Universitätsklinikum Leipzig ( Site 0762)
Leipzig 2879139, Saxony 2842566, 04103
Status
Address
Universitaetsklinikum Schleswig-Holstein Campus Kiel-Hautklinik ( Site 0767)
Kiel 2891122, Schleswig-Holstein 2838632, 24105
Status
Address
Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 0756)
Berlin 2950159, , 10117
Status
Address
Universitaetsklinikum Hamburg-Eppendorf ( Site 0752)
Hamburg 2911298, , 20246
Status
Address
Artemis hospital ( Site 1551)
Gurugram 1270642, Haryana 1270260, 122001
Status
Address
Tata Memorial Hospital-Medical Oncology ( Site 1550)
Mumbai 1275339, Maharashtra 1264418, 400012
Status
Address
All India Institute of Medical Sciences-Medical oncology ( Site 1552)
New Delhi 1261481, National Capital Territory of Delhi 1273293, 110029
Status
Address
St. James's Hospital-Cancer clinical trials office ( Site 0900)
Dublin 2964574, , D08 E9P6
Status
Address
Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 0902)
Dublin 2964574, , Dublin 9
Status
Address
Emek Medical Center-oncology ( Site 0952)
Afula 295740, , 1834111
Status
Address
Soroka Medical Center ( Site 0953)
Beersheba 295530, , 8410101
Status
Address
Rambam Health Care Campus-Oncology Division ( Site 0955)
Haifa 294801, , 3109601
Status
Address
Hadassah Medical Center ( Site 0951)
Jerusalem 281184, , 9112001
Status
Address
Rabin Medical Center-Oncology ( Site 0954)
Petah Tikva 293918, , 4941492
Status
Address
Sheba Medical Center-ONCOLOGY ( Site 0950)
Ramat Gan 293788, , 5265601
Status
Address
Instituto Tumori Giovanni Paolo II ( Site 1003)
Bari 3182351, Apulia 3169778, 70124
Status
Address
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1004)
Meldola 3173635, Emilia-Romagna 3177401, 47014
Status
Address
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1000)
Milan 3173435, Lombardy 3174618, 20133
Status
Address
A.O.U. Policlinico Paolo Giaccone-Depatment of Discipline Chirurgiche, Oncologiche e Stomatologiche
Palermo 2523920, Sicily 2523119, 90129
Status
Address
Azienda Ospedaliero Universitaria Senese ( Site 1005)
Siena 3166548, Tuscany 3165361, 53100
Status
Address
AO Santa Maria della Misericordia ( Site 1006)
Perugia 3171180, Umbria 3165048, 06129
Status
Address
Istituto Europeo di Oncologia IRCCS ( Site 1008)
Milan 6951411, , 20141
Status
Address
Azienda Ospedaliero Universitaria ( Site 1002)
Modena 3173331, , 41125
Status
Address
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1001)
Napoli 9031661, , 80131
Status
Address
Nagoya University Hospital ( Site 1753)
Nagoya 1856057, Aichi-ken 1865694, 466-8560
Status
Address
Sapporo Medical University Hospital ( Site 1755)
Sapporo 2128295, Hokkaido 2130037, 060-8543
Status
Address
Niigata Cancer Center Hospital ( Site 1751)
Niigata 1855431, Niigata 1855429, 951-8566
Status
Address
Shizuoka Cancer Center ( Site 1752)
Nagaizumi-cho,Sunto-gun, Shizuoka 1851715, 411-8777
Status
Address
National Cancer Center Hospital ( Site 1750)
Chuo-ku, Tokyo 1850144, 104-0045
Status
Address
Osaka International Cancer Institute ( Site 1754)
Osaka 1853909, , 541-8567
Status
Address
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1501)
Tauranga 2208032, Bay of Plenty 2182560, 3112
Status
Address
New Zealand Clinical Research (Christchurch) ( Site 1509)
Christchurch 2192362, Canterbury 2192628, 8011
Status
Address
P3 Research - Palmerston North ( Site 1510)
Palmerston North 2185018, Manawatu-Wanganui 2179671, 4414
Status
Address
Dunedin Hospital ( Site 1511)
Dunedin 2191562, Otago 6612109, 9016
Status
Address
Harbour Cancer & Wellness ( Site 1508)
Auckland 2193733, , 0627
Status
Address
Szpital Kliniczny im. H. Swiecickiego nr 2-Oddział Kliniczny Onkologii Klinicznej i Doświadczalnej (
Poznan 3088171, Greater Poland Voivodeship 3337498, 60-780
Status
Address
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1061)
Bydgoszcz 3102014, Kuyavian-Pomeranian Voivodeship 3337500, 85-796
Status
Address
Pratia MCM Krakow ( Site 1053)
Krakow 3094802, Lesser Poland Voivodeship 858786, 30-727
Status
Address
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1058)
Siedlce 759412, Masovian Voivodeship 858787, 08-110
Status
Address
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw 756135, Masovian Voivodeship 858787, 02-781
Status
Address
Bialostockie Centrum Onkologii ( Site 1065)
Bialystok 776069, Podlaskie Voivodeship 858789, 15-027
Status
Address
Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site
Gdansk 3099434, Pomeranian Voivodeship 3337496, 80-214
Status
Address
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oncologii, Chemioterapii ( Site 1064)
Słupsk 3085450, Pomeranian Voivodeship 3337496, 76-200
Status
Address
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1056)
Gliwice 3099230, Silesian Voivodeship 3337497, 44-101
Status
Address
Zachodniopomorskie Centrum Onkologii ( Site 1063)
Szczecin 3083829, West Pomeranian Voivodeship 3337499, 71-730
Status
Address
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 1054)
Kielce 769250, Świętokrzyskie Voivodeship 858790, 25-734
Status
Address
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 1161)
Port Elizabeth 964420, Eastern Cape 1085593, 6055
Status
Address
Medical Oncology Centre of Rosebank ( Site 1160)
Johannesburg 993800, Gauteng 1085594, 2196
Status
Address
Wilgers Oncology Centre ( Site 1154)
Pretoria 964137, Gauteng 1085594, 0040
Status
Address
Curo Oncology ( Site 1158)
Pretoria 964137, Gauteng 1085594, 0084
Status
Address
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 1152)
Pretoria 964137, Gauteng 1085594, 0181
Status
Address
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 1151)
Sandton 957654, Gauteng 1085594, 2196
Status
Address
The Oncology Centre ( Site 1157)
Durban 1007311, KwaZulu-Natal 972062, 4091
Status
Address
Abraham Oncology ( Site 1150)
Richards Bay 962367, KwaZulu-Natal 972062, 3900
Status
Address
Cape Town Oncology Trials ( Site 1155)
Cape Town 3369157, Western Cape 1085599, 7570
Status
Address
Cancercare Rondebosch Oncology-Clinical trials ( Site 1159)
Rondebosch 7302802, Western Cape 1085599, 7700
Status
Address
Seoul National University Hospital-Oncology ( Site 1600)
Seoul 1835848, , 03080
Status
Address
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1601)
Seoul 1835848, , 03722
Status
Address
Samsung Medical Center-Division of Hematology/Oncology ( Site 1602)
Seoul 1835848, , 06351
Status
Address
Institut Català d'Oncologia - L'Hospitalet ( Site 1202)
L'Hospitalet de Llobregat 3120619, Barcelona, 08908
Status
Address
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1203)
Doniostia - San Sebastian, Gipuzkoa, 20014
Status
Address
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1204)
Madrid 3117735, Madrid, Comunidad de, 28034
Status
Address
H.R.U Málaga - Hospital General-Oncology ( Site 1201)
Málaga 2514256, Malaga, 29011
Status
Address
Hospital General Universitario de Valencia ( Site 1200)
Valencia 2509954, Valenciana, Comunitat, 46014
Status
Address
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1205)
Seville 2510911, , 41009
Status
Address
Länssjukhuset Ryhov-Onkologkliniken ( Site 1253)
Jönköping 2702979, Jönköping County 2702976, 553 05
Status
Address
Karolinska Universitetssjukhuset Solna ( Site 1252)
Stockholm 2673730, Stockholm County 2673722, 171 64
Status
Address
University Hospital Basel ( Site 1303)
Basel 2661604, Canton of Basel-City 2661602, 4056
Status
Address
Inselspital Bern ( Site 1301)
Bern 2661552, Canton of Bern 2661551, 3010
Status
Address
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1307)
Geneva 2660646, Canton of Geneva 2660645, 1211
Status
Address
CHUV (centre hospitalier universitaire vaudois) ( Site 1304)
Lausanne 2659994, Canton of Vaud 2658182, 1011
Status
Address
UniversitätsSpital Zürich-Dermatology ( Site 1300)
Zürich Flughafen, Canton of Zurich 2657895, 8058
Status
Address
Ospedale Regionale Bellinzona e Valli ( Site 1308)
Bellinzona 2661567, Canton Ticino 2658370, 6500
Status
Address
Hôpital de Sion ( Site 1305)
Sion 2658576, Valais 2658205, 1951
Status
Address
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 1306)
Sankt Gallen 2658822, , 9007
Status
Address
Ankara City Hospital-Medical Oncology ( Site 1357)
Çankaya 6955677, Ankara 323784, 06800
Status
Address
I.E.U. Medical Point Hastanesi-Oncology ( Site 1360)
Izmir, Karsiyaka, İzmir 311044, 009035575
Status
Address
Hacettepe Universite Hastaneleri ( Site 1363)
Ankara 323786, , 06230
Status
Address
Liv Hospital Ankara-Oncology ( Site 1353)
Ankara 323786, , 06680
Status
Address
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1355)
Antalya 323777, , 07059
Status
Address
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1358)
Istanbul 745044, , 34722
Status
Address
Mersin Sehir Eğitim ve Araştırma Hastanesi-Oncology ( Site 1361)
Mersin 304531, , 33240
Status
Address
Ondokuz Mayıs Universitesi-Oncology department ( Site 1359)
Samsun 740264, , 55139
Status
Address
Addenbrooke's Hospital ( Site 1400)
Cambridge 2653941, Cambridgeshire, CB2 2QQ
Status
Address
University College London Hospital ( Site 1405)
London 2643743, England 6269131, NW1 2PG
Status
Address
Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 1401)
London 2643743, London, City of, SE1 9RT
